TransMedics Group, Inc.
HealthcareNASDAQ:TMDX · NASDAQ Global Market
-$0.68 today
Vol 0.66M · Avg 1.31M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$635.9M of revenue converted into $171.9M of net income for the selected period. Gross margin is 59.1% and net margin is 27.2%, showing how much revenue survives after costs and taxes. EPS is $4.37, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $605.5M +37.1% | $441.5M +82.7% | $241.6M +158.5% | $93.5M +208.8% | $30.3M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $242.7M +35.2% | $179.5M +105.0% | $87.5M +210.5% | $28.2M +209.6% | $9.1M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $362.8M +38.4% | $262.1M +70.1% | $154.1M +136.1% | $65.3M +208.5% | $21.2M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 59.9% +0.6pp | 59.4% -4.4pp | 63.8% -6.1pp | 69.8% -0.1pp | 69.9% | 9.8% | 28.9% | 38.3% |
| Research & Development | $69.1M +23.4% | $56.0M -11.5% | $63.3M +136.0% | $26.8M +20.2% | $22.3M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $185.2M +9.8% | $168.6M +41.0% | $119.6M +71.0% | $69.9M +82.6% | $38.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $254.2M +13.2% | $224.6M +22.8% | $182.8M +89.0% | $96.7M +59.6% | $60.6M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $27.2M +37.6% | $19.8M +141.6% | $8.2M +135.1% | $3.5M +91.4% | $1.8M | $374.2M | $1.2B | $631.8M |
| EBITDA | $148.5M +112.3% | $69.9M +1008.0% | -$7.7M +73.4% | -$29.0M +24.8% | -$38.5M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 24.5% +8.7pp | 15.8% +19.0pp | -3.2% +27.8pp | -31.0% +96.2pp | -127.2% | 5.6% | 46.3% | 42.0% |
| Operating Income | $108.6M +189.6% | $37.5M +230.5% | -$28.7M +8.6% | -$31.4M +20.3% | -$39.4M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 17.9% +9.4pp | 8.5% +20.4pp | -11.9% +21.7pp | -33.6% +96.7pp | -130.3% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 | $0 -100.0% | $12.5M +1288.9% | $900.0K | $0 | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $13.8M -4.4% | $14.4M +33.5% | $10.8M +189.6% | $3.7M -3.8% | $3.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | -$1.1M +38.2% | -$1.7M -183.5% | $2.1M +143.5% | -$4.7M +0.5% | -$4.8M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $107.5M +200.5% | $35.8M +234.2% | -$26.7M +26.3% | -$36.2M +18.1% | -$44.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 17.8% +9.7pp | 8.1% +19.1pp | -11.0% +27.7pp | -38.7% +107.3pp | -146.0% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | -$82.8M -26292.7% | $316.0K +119.2% | -$1.6M -2589.4% | $66.0K +83.3% | $36.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | $190.3M +436.6% | $35.5M +241.7% | -$25.0M +30.9% | -$36.2M +18.1% | -$44.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | 31.4% +23.4pp | 8.0% +18.4pp | -10.4% +28.4pp | -38.8% +107.3pp | -146.1% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $6 +423.4% | $1 +239.0% | -$1 +37.4% | -$1 +23.1% | -$2 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $5 +382.2% | $1 +231.2% | -$1 +37.4% | -$1 +23.1% | -$2 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $34.0M +2.3% | $33.2M +2.2% | $32.5M +10.0% | $29.6M +7.0% | $27.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $40.5M +15.1% | $35.2M +8.3% | $32.5M +10.0% | $29.6M +7.0% | $27.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Bruker Corporation
NASDAQ:BRKR
$8.26B
Glaukos Corporation
NYSE:GKOS
$7.45B
Oscar Health, Inc.
NYSE:OSCR
$7.33B
Kymera Therapeutics, Inc.
NASDAQ:KYMR
$7.09B
Immunovant, Inc.
NASDAQ:IMVT
$6.90B
Hinge Health, Inc.
NYSE:HNGE
$5.06B
Indivior Pharmaceuticals Inc
NASDAQ:INDV
$4.80B
Akero Therapeutics, Inc.
AKRO
$4.50B
NewAmsterdam Pharma Company N.V.
NASDAQ:NAMS
$3.55B
Option Care Health, Inc.
NASDAQ:OPCH
$3.26B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does TMDX generate?
TransMedics Group, Inc. (TMDX) reported $605.49M of revenue in fiscal 2025.
Is TMDX profitable?
TransMedics Group, Inc. (TMDX) reported $190.29M of net income, with a net margin of 31.4%.
Explore More
Continue the stock analysis
Jump to another research area for this company.